Literature DB >> 20564743

Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients.

Monika L Metzger1, Melissa M Hudson, Matthew J Krasin, Jianrong Wu, Sue C Kaste, Larry E Kun, John T Sandlund, Scott C Howard.   

Abstract

BACKGROUND: Pediatric Hodgkin lymphoma (HL) is a highly curable disease; however, prognostic factors for the survival of patients who develop recurrent disease have not been clearly defined.
METHODS: This was a retrospective analysis of 50 pediatric patients with HL who relapsed or progressed between 1990 and 2006 and who were retrieved with intense cytoreductive treatment regimens followed by autologous stem cell transplantation and radiation therapy. A Cox proportional hazards model was used to determine risk factors for second treatment failure and death.
RESULTS: The median patient age was 16.1 years (range, 4.9-22.1 years) at the time of HL diagnosis. Fifteen patients developed progressive disease during therapy, 14 patients relapsed early, and 21 patients relapsed late. Patients who remained alive at the time of this study had been followed for a median of 4.4 years (range, 1.2-16.6 years). The 5-year overall survival rate for patients who had an inadequate response (n = 14) to initial salvage therapy was only 17.9% (95% confidence interval [CI], 3.1%-42.5%) compared with 97.2% (95% CI, 81.9%-99.6%) for patients who responded (n = 36; P < .0001). In a multivariate Cox regression analysis of overall survival, an inadequate response to initial salvage therapy was the only significant variable (hazard ratio, 43.6; 95% CI, 5.4-354; P = .0004).
CONCLUSIONS: The current results indicated that pediatric patients with relapsed HL who have an inadequate response after initial primary salvage chemotherapy have a very poor prognosis and should be considered for novel therapies directed at biologic or immunologic targets.
© 2010 American Cancer Society.

Entities:  

Mesh:

Year:  2010        PMID: 20564743      PMCID: PMC2936658          DOI: 10.1002/cncr.25225

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  34 in total

1.  Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).

Authors:  A Josting; I Kàtay; U Rueffer; S Winter; H Tesch; A Engert; V Diehl; P D Wickramanayake
Journal:  Ann Oncol       Date:  1998-03       Impact factor: 32.976

2.  High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party.

Authors:  J W Sweetenham; A M Carella; G Taghipour; D Cunningham; R Marcus; A Della Volpe; D C Linch; N Schmitz; A H Goldstone
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

3.  The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.

Authors:  R Chopra; A K McMillan; D C Linch; S Yuklea; G Taghipour; R Pearce; K G Patterson; A H Goldstone
Journal:  Blood       Date:  1993-03-01       Impact factor: 22.113

4.  Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.

Authors:  F Moog; M Bangerter; C G Diederichs; A Guhlmann; J Kotzerke; E Merkle; O Kolokythas; F Herrmann; S N Reske
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

5.  Extranodal malignant lymphoma: detection with FDG PET versus CT.

Authors:  F Moog; M Bangerter; C G Diederichs; A Guhlmann; E Merkle; N Frickhofen; S N Reske
Journal:  Radiology       Date:  1998-02       Impact factor: 11.105

6.  Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.

Authors:  J E Lancet; A P Rapoport; R Brasacchio; S Eberly; R F Raubertas; T Linder; A Muhs; R E Duerst; C N Abboud; C H Packman; J F DiPersio; L S Constine; J M Rowe; J L Liesveld
Journal:  Bone Marrow Transplant       Date:  1998-08       Impact factor: 5.483

7.  High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.

Authors:  M Crump; A M Smith; J Brandwein; F Couture; H Sherret; D M Sutton; J G Scott; J McCrae; C Murray; D Pantalony
Journal:  J Clin Oncol       Date:  1993-04       Impact factor: 44.544

8.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

Authors:  D Hasenclever; V Diehl
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

9.  High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices.

Authors:  YeeYie E Lieskovsky; Sarah S Donaldson; Mylin A Torres; Ruby M Wong; Michael D Amylon; Michael P Link; Rajni Agarwal
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

10.  Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.

Authors:  Melissa M Hudson; Matthew Krasin; Michael P Link; Sarah S Donaldson; Catherine Billups; Thomas E Merchant; Larry Kun; Amy L Billet; Sue Kaste; Nancy J Tarbell; Scott Howard; Alison M Friedmann; Craig A Hurwitz; Jeffrey A Young; Karen C Marcus; Shesh Rai; Traci Cowan; Howard J Weinstein
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

View more
  12 in total

1.  Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group.

Authors:  Stephan D Voss; Lu Chen; Louis S Constine; Allen Chauvenet; Thomas J Fitzgerald; Sue C Kaste; Thomas Slovis; Cindy L Schwartz
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

2.  Patterns of Relapse After Salvage Autologous Stem Cell Transplant for Hodgkin's Lymphoma: Should Sites of Relapse Relative to Initially Involved Sites Be Used to Guide Indications for Peri-Transplant Radiation Therapy.

Authors:  Joshua C Farris; Alex Ritter; Michael D Craig; Nilay Shah; Lauren Veltri; Abraham S Kanate; Kelly Ross; John A Vargo
Journal:  Pract Radiat Oncol       Date:  2018-12-21

Review 3.  Pharmacotherapeutic Management of Pediatric Lymphoma.

Authors:  Christine Mauz-Körholz; Natascha Ströter; Julia Baumann; Ante Botzen; Katharina Körholz; Dieter Körholz
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

4.  Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience.

Authors:  Lisa Giulino-Roth; Tara O'Donohue; Zhengming Chen; Tanya M Trippett; Elizabeth Klein; Nancy A Kernan; Rachel Kobos; Susan E Prockop; Andromachi Scaradavou; Neerav Shukla; Peter G Steinherz; Alison J Moskowitz; Craig H Moskowitz; Farid Boulad
Journal:  Leuk Lymphoma       Date:  2017-11-29

5.  Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks.

Authors:  Jennifer M Yeh; Lisa Diller
Journal:  Blood       Date:  2012-07-23       Impact factor: 22.113

Review 6.  Management of Hodgkins Lymphoma: ICMR Consensus Document.

Authors:  Venkatraman Radhakrishnan; Gauri Kapoor; Brijesh Arora; Deepak Bansal; Tushar Vora; Maya Prasad; Girish Chinnaswamy; Siddharth Laskar; Sandeep Agarwala; Tanvir Kaur; G K Rath; Sameer Bakhshi
Journal:  Indian J Pediatr       Date:  2017-03-30       Impact factor: 1.967

7.  Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy.

Authors:  Christopher L Tinkle; Noelle L Williams; Huiyun Wu; Jianrong Wu; Sue C Kaste; Barry L Shulkin; Aimee C Talleur; Jamie E Flerlage; Melissa M Hudson; Monika L Metzger; Matthew J Krasin
Journal:  Radiother Oncol       Date:  2019-02-05       Impact factor: 6.280

8.  A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.

Authors:  P Satwani; K W Ahn; J Carreras; H Abdel-Azim; M S Cairo; A Cashen; A I Chen; J B Cohen; L J Costa; C Dandoy; T S Fenske; C O Freytes; S Ganguly; R P Gale; N Ghosh; M S Hertzberg; R J Hayashi; R T Kamble; A S Kanate; A Keating; M A Kharfan-Dabaja; H M Lazarus; D I Marks; T Nishihori; R F Olsson; T D Prestidge; J M Rolon; B N Savani; J M Vose; W A Wood; D J Inwards; V Bachanova; S M Smith; D G Maloney; A Sureda; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2015-08-03       Impact factor: 5.483

Review 9.  Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.

Authors:  Poonam Nagpal; Mohamed R Akl; Nehad M Ayoub; Tatsunari Tomiyama; Tasheka Cousins; Betty Tai; Nicole Carroll; Themba Nyrenda; Pritish Bhattacharyya; Michael B Harris; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  Oncotarget       Date:  2016-10-11

10.  Prognostic Factors and a New Prognostic Index Model for Children and Adolescents with Hodgkin's Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation: A Multicenter Study of the Turkish Pediatric Bone Marrow Transplantation Study Group.

Authors:  Vural Kesik; Erman Ataş; Musa Karakükcü; Serap Aksoylar; Fatih Erbey; Nurdan Taçyıldız; Alphan Küpesiz; Haldun Öniz; Ekrem Ünal; Savaş Kansoy; Gülyüz Öztürk; Murat Elli; Zühre Kaya; Emel Ünal; Volkan Hazar; Şebnem Yılmaz Bengoa; Gülsün Karasu; Didem Atay; Ayhan Dağdemir; Hale Ören; Ülker Koçak; M Akif Yeşilipek
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.